Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Critical Care Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Conversations with Dr Bauchner (38:26)

Peter Piot, MD, PhD, director of The London School of Hygiene and Tropical Medicine, is a legend in global health, having been involved in identification of HIV and Ebola virus in Africa. He was founding executive director of UNAIDS and Under Secretary-General of the United Nations from 1995 to 2008. He joins JAMA's Q&A series to discuss the global public health response to COVID-19 past,...

Huang  C, Wang  Y, Li  X,  et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.   Lancet. 2020;395(10223):497-506. PubMedGoogle ScholarCrossref
WHO. Novel coronavirus (COVID-19) situation. Updated March 24, 2020.
Wu  Z, McGoogan  JM.  Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.   JAMA. 2020. Published online February 24, 2020. doi:10.1001/jama.2020.2648PubMedGoogle Scholar
Lu  H.  Drug treatment options for the 2019-new coronavirus (2019-nCoV).   Biosci Trends. 2020;14(1):69-71. PubMedGoogle ScholarCrossref
Chen  L, Xiong  J, Bao  L, Shi  Y.  Convalescent plasma as a potential therapy for COVID-19.   Lancet Infect Dis. 2020;S1473-3099(20)30141-9. PubMedGoogle Scholar
Kraft  CS, Hewlett  AL, Koepsell  S,  et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit.  The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States.   Clin Infect Dis. 2015;61(4):496-502. PubMedGoogle ScholarCrossref
van Griensven  J, Edwards  T, de Lamballerie  X,  et al; Ebola-Tx Consortium.  Evaluation of convalescent plasma for Ebola virus disease in Guinea.   N Engl J Med. 2016;374(1):33-42. PubMedGoogle ScholarCrossref
Florescu  DF, Kalil  AC, Hewlett  AL,  et al.  Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease.   Clin Infect Dis. 2015;61(6):969-973. PubMedGoogle ScholarCrossref
Zhou  B, Zhong  N, Guan  Y.  Treatment with convalescent plasma for influenza A (H5N1) infection.   N Engl J Med. 2007;357(14):1450-1451. PubMedGoogle ScholarCrossref
Hung  IF, To  KK, Lee  CK,  et al.  Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.   Clin Infect Dis. 2011;52(4):447-456. PubMedGoogle ScholarCrossref
Burnouf  T, Radosevich  M.  Treatment of severe acute respiratory syndrome with convalescent plasma.   Hong Kong Med J. 2003;9(4):309.PubMedGoogle Scholar
Cheng  Y, Wong  R, Soo  YO,  et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong.   Eur J Clin Microbiol Infect Dis. 2005;24(1):44-46.PubMedGoogle ScholarCrossref
Yang  Y, Yang  M, Shen  C,  et al Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Preprint. medRxiv. Preprint posted online February 17, 2020. doi:10.1101/2020.02.11.20021493
Villar  J, Blanco  J, del Campo  R,  et al; Spanish Initiative for Epidemiology, Stratification & Therapies for ARDS (SIESTA) Network.  Assessment of PaO₂/FiO₂ for stratification of patients with moderate and severe acute respiratory distress syndrome.   BMJ Open. 2015;5(3):e006812. doi:10.1136/bmjopen-2014-006812PubMedGoogle Scholar
Liu  C, Yang  Y, Gao  Y,  et al Viral architecture of SARS-CoV-2 with post-fusion spike revealed by Cryo-EM. bioRxiv. Preprint posted online March 5, 2020. doi:10.1101/2020.03.02.972927
Yeh  KM, Chiueh  TS, Siu  LK,  et al.  Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital.   J Antimicrob Chemother. 2005;56(5):919-922. PubMedGoogle ScholarCrossref
Mair-Jenkins  J, Saavedra-Campos  M, Baillie  JK,  et al; Convalescent Plasma Study Group.  The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.   J Infect Dis. 2015;211(1):80-90. PubMedGoogle ScholarCrossref
Ng  KT, Oong  XY, Lim  SH,  et al.  Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections.   Clin Infect Dis. 2018;67(2):261-268. PubMedGoogle ScholarCrossref
de Jong  MD, Simmons  CP, Thanh  TT,  et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.   Nat Med. 2006;12(10):1203-1207. PubMedGoogle ScholarCrossref
Shen  C, Chen  J, Li  R,  et al.  A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.   Sci Transl Med. 2017;9(412):eaam5752.PubMedGoogle Scholar
Shen  C, Zhang  M, Chen  Y,  et al.  An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.   Theranostics. 2019;9(1):210-231. PubMedGoogle ScholarCrossref
Wang  C, Li  W, Drabek  D,  et al A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv. Preprint posted online March 12, 2020. doi:10.1101/2020.03.11.987958
Lu  CL, Murakowski  DK, Bournazos  S,  et al.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.   Science. 2016;352(6288):1001-1004. PubMedGoogle ScholarCrossref
Preliminary Communication
March 27, 2020

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Author Affiliations
  • 1Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
  • 2Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China
JAMA. 2020;323(16):1582-1589. doi:10.1001/jama.2020.4783
Key Points

Question  Could administration of convalescent plasma transfusion be beneficial in the treatment of critically ill patients with coronavirus disease 2019 (COVID-19)?

Findings  In this uncontrolled case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome (ARDS), administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status.

Meaning  These preliminary findings raise the possibility that convalescent plasma transfusion may be helpful in the treatment of critically ill patients with COVID-19 and ARDS, but this approach requires evaluation in randomized clinical trials.


Importance  Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.

Objective  To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Design, Setting, and Participants  Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 <300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.

Exposures  Patients received transfusion with convalescent plasma with a SARS-CoV-2–specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.

Main Outcomes and Measures  Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.

Results  All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2–specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.

Conclusions and Relevance  In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.